Female genital tract metastasis of lung adenocarcinoma with EGFR mutations: Report of two cases

被引:1
作者
Run-Lan Yan [1 ]
Jie Wang [1 ]
Jian-Ya Zhou [1 ]
Zhen Chen [2 ]
Jian-Ying Zhou [1 ]
机构
[1] Department of Respiratory Diseases, First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University
[2] Department of Pathology, First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University
基金
中国国家自然科学基金;
关键词
Lung adenocarcinoma; Epidermal growth factor receptor; Metastasis; Ovary; Cervix; Case report;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND The female genital tract is an uncommon site of involvement for extra-genital malignancies. Ovarian metastases have been described as disseminations of lung adenocarcinoma; rare cases of secondary localizations in the cervix, adnexa, and vagina have also been reported in the literature. Here, we report two cases of advanced lung adenocarcinoma with female genital tract metastasis.CASE SUMMARY The first case was a 41-year-old woman with stage IV lung adenocarcinoma metastasizing to the cervix. Immunohistochemistry of the cervical biopsy specimen revealed thyroid transcription factor(TTF)-1(+), cytokeratin(CK)-7(+),and(CK)-20(-). Gene mutational analysis showed epidermal growth factor receptor(EGFR) L858 R mutation in exon 21. She had a positive response to gefitinib, for both the pulmonary mass and cervical neoplasm. The second case was a 29-year-old woman who was diagnosed with stage IV lung adenocarcinoma with EGFR mutation. After 12 mo of treatment with icotinib,ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790 M mutation.CONCLUSION Immunohistochemistry and gene mutational testing have greatly helped in locating the initial tumor site when both pulmonary and female genital tract neoplasms exist.
引用
收藏
页码:1515 / 1521
页数:7
相关论文
共 15 条
  • [1] Challenges in molecular testing in non-smallcell lung cancer patients with advanced disease. Hiley CT,Le Quesne J,Santis G,Sharpe R,de Castro DG,Middleton G,et al. The Lancet . 2016
  • [2] Lung Carcinoma Metastatic to the Ovary: A Clinicopathologic Study of 32 Cases Emphasizing Their Morphologic Spectrum and Problems in Differential Diagnosis[J] . Julie A Irving,Robert H Young. &nbspThe American Journal of Surgical Pathology . 2005 (8)
  • [3] Carcinomas of Ovary and Lung With Clear Cell Features: Can Immunohistochemistry Help in Differential Diagnosis?[J] . Nicole R. Howell,Wenxin Zheng,Liang Cheng,Carmen Tornos,Philip Kane,Michael Pearl,Eva Chalas,Sharon X. Liang. &nbspInternational Journal of Gynecological Pathology . 2007 (2)
  • [4] Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
    Xu, Yan
    Liu, Hongyu
    Chen, Jun
    Zhou, Qinghua
    [J]. CANCER BIOLOGY & THERAPY, 2010, 9 (08) : 572 - 582
  • [5] Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement[J] . Ayako Fujiwara,Masahiko Higashiyama,Takashi Kanou,Toshiteru Tokunaga,Jiro Okami,Ken Kodama,Kazumi Nishino,Yasuhiko Tomita,Isamu Okamoto. &nbspLung Cancer . 2013
  • [6] Tumour-to-tumour metastasis of lung adenocarcinoma to ovarian serous cystadenoma
    Min, K. -W.
    Paik, S. S.
    Han, H.
    Kim, W. S.
    Jang, K.
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 34 (07) : 650 - +
  • [7] Plasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer
    Lam, David C. L.
    Tam, Terence C. C.
    Lau, Kenneth M. K.
    Wong, Wai-Mui
    Hui, Christopher K. M.
    Lam, Jamie C. M.
    Wang, Julie K. L.
    Lui, Macy M. S.
    Ho, James C. M.
    Ip, Mary S. M.
    [J]. CLINICAL LUNG CANCER, 2015, 16 (06) : 507 - 513
  • [8] Metastases to the female genital tract. Analysis of 325 cases. Mazur M T,Hsueh S,Gersell D J. Cancer . 1984
  • [9] Ovarian metastasis from non?small cell lung cancer with ALK and EGFRmutations: A report of two cases[J] . Rosemary Mushi,Yumei Yang,Qian Cai,Ruiguang Zhang,Gang Wu,Xiaorong Dong. &nbspOncology Letters . 2016 (6)
  • [10] Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study[J] . Glenwood Goss,Chun-Ming Tsai,Frances A Shepherd,Lyudmila Bazhenova,Jong Seok Lee,Gee-Chen Chang,Lucio Crino,Miyako Satouchi,Quincy Chu,Toyoaki Hida,Ji-Youn Han,Oscar Juan,Frank Dunphy,Makoto Nishio,Jin-Hyoung Kang,Margarita Majem,Helen Mann,Mireille Cantarini,Serban Ghiorghiu,Tetsuya Mitsudomi. &nbspThe Lancet Oncology . 2016 (12)